Advances in the care of children with lupus nephritis

Pediatric Research

Volumn 81, Issue 3, 2017, Pages 406-414

  Wenderfer, Scott E ^a   Ruth, Natasha M ^b   Brunner, Hermine I ^c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

CHILD; CHILD CARE; CHILDHOOD DISEASE; CHRONIC DISEASE; COHORT ANALYSIS; CONSENSUS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOPSY; FEMALE; HISTORY; KIDNEY; MALE; METABOLISM; PATHOLOGY; PEDIATRICS; PRESCHOOL CHILD; PROCEDURES;

BIOMARKERS; BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; PEDIATRICS; PROGNOSIS;

EID: 85016445174     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2016.247     Document Type: Review

References (91)

1. Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythe-matosus with onset before adulthood. Arthritis Care Res (Hoboken) 2012;64:1787-93.
2. Livingston B, Bonner A, Pope J. Diferences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20:1345-55.
3. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demo-graphics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid benefciary population. Arthritis Rheum 2012;64:2669-76.
4. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford M W, Isen-berg DA. Diferences in disease phenotype and severity in SLE across age groups. Lupus 2016;25(14):1542-50.
5. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difer-ence in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556-62.
6. Hagge W W, Burke EC, Stickler GB. Treatment of systemic lupus erythema-tosus complicated by nephritis in children. Pediatrics 1967;40:822-7.
7. Meislin AG, Rothfeld N. Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 1968;42:37-49.
8. Caeiro F, Michielson FM, Bernstein R, Hughes GR, Ansell BM. Systemic lupus erythematosus in childhood. Ann Rheum Dis 1981;40:325-31.
9. Hargraves MM. Production in vitro of the L.E. cell phenomenon; use of normal bone marrow elements and blood plasma from patients with acute disseminated lupus erythematosus. Proc Staf Meet Mayo Clin 1949;24:234-7.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classifcation of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
11. Tarr T, Dérfalvi B, Gyori N, et al. Similarities and diferences between pediatric and adult patients with systemic lupus erythematosus. Lupus 2015;24:796-803.
12. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifcation criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
13. Sag E, Tartaglione A, Batu ED, et al. Performance of the new SLICC classi-fcation criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol 2014;32:440-4.
14. Fonseca AR, Gaspar-Elsas MI, Land MG, de Oliveira SK. Comparison between three systems of classifcation criteria in juvenile systemic lupus erythematous. Rheumatology (Oxford) 2015;54:241-7.
15. Sinha MD, Lewis MA, Bradbury MG, Webb NJ. Percutaneous real-time ultrasound-guided renal biopsy by automated biopsy gun in children: safety and complications. J Nephrol 2006;19:41-4.
16. Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012;7:1591-7.
17. Weening JJ, D'Agati VD, Schwartz MM, et al. The classifcation of glomeru-lonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
18. Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988;8:85-9.
19. Boneparth A, Ilowite NT; CARRA Registry Investigators. Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: a cross-sectional analysis of the CARRA Registry. Lupus 2014;23:898-904.
20. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635-42.
21. Zappitelli M, Dufy C, Bernard C, et al. Clinicopathological study of the WHO classifcation in childhood lupus nephritis. Pediatr Nephrol 2004;19:503-10.
22. Rianthavorn P, Buddhasri A. Long-term renal outcomes of childhood-onset global and segmental difuse proliferative lupus nephritis. Pediatr Nephrol 2015;30:1969-76.
23. Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correla-tions of paediatric lupus nephritis. Pediatr Nephrol 2007;22:77-83.
24. Austin HA 3rd, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-91.
25. Hill GS, Delahousse M, Nochy D, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000;58: 1160-73.
26. Zappitelli M, Dufy CM, Bernard C, Gupta IR. Evaluation of activity, chro-nicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol 2008;23:83-91.
27. Brunner HI, Bennett MR, Abulaban K, et al. Development of a novel renal activity index of lupus nephritis in children and young adults. Arthritis Care Res (Hoboken) 2016;68:1003-11.
28. Wenderfer SE, Lane JC, Shatat IF, von Scheven E, Ruth NM. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest Pediatric Nephrology Consortium and the Childhood Arthritis and Rheumatology Research Alliance. Pediatr Rheumatol Online J 2015;13:26.
29. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-asso-ciated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009;60:2772-81.
30. Suzuki M, Wiers K, Brooks EB, et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res 2009;65:530-6.
31. Watson L, Tullus K, Pilkington C, et al. Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study. Pediatr Nephrol 2014;29:397-405.
32. Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010;49:960-71.
33. Rubinstein TB, Putterman C, Goilav B. Biomarkers for CNS involvement in pediatric lupus. Biomark Med 2015;9:545-58.
34. Abulaban KM, Fall N, Nunna R, et al. Relationship of cell-free urine MicroRNA with lupus nephritis in children. Pediatr Rheumatol Online J 2016;14:4.
35. Sule SD, Moodalbail DG, Burnham J, Fivush B, Furth SL. Predictors of kidney disease in a cohort of pediatric patients with lupus. Lupus 2015;24: 862-8.
36. Mina R, von Scheven E, Ardoin SP, et al.; Carra SLE Subcommittee. Con-sensus treatment plans for induction therapy of newly diagnosed prolif-erative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:375-83.
37. Kavanaugh AF, Solomon DH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-55.
38. Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford) 2005;44:1227-32.
39. Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012;12:CD002922.
40. Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse meth-ylprednisolone therapy in difuse proliferative lupus nephritis. J Pediatr 1982;101:137-41.
41. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus ery-thematosus. J Pediatr 2000;136:243-7.
42. Lau KK, Ault BH, Jones D P, Butani L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 2008;22:282-8.
43. Silverman ED, Lang B. An overview of the treatment of childhood SLE. Scand J Rheumatol 1997;26:241-6.
44. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
45. Falcini F, Capannini S, Martini G, et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 2009;18: 139-43.
46. Kizawa T, Nozawa T, Kikuchi M, et al. Mycophenolate mofetil as mainte-nance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol 2015;25:210-4.
47. Buratti S, Szer IS, Spencer CH, Bartosh S, Reif A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythe-matosus. J Rheumatol 2001;28:2103-8.
48. Tamirou F, D'Cruz D, Sangle S, et al.; MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing aza-thioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016;75:526-31.
49. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44.
50. Fu LW, Yang LY, Chen W P, Lin CY. Clinical efcacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998;37:217-21.
51. Aragon E, Resontoc L P, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus 2016;25:399-406.
52. Pereira T, Abitbol CL, Seeherunvong W, et al. Tree decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 2011;6:2192-9.
53. Willems M, Haddad E, Niaudet P, et al.; French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythema-tosus. J Pediatr 2006;148:623-7.
54. Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014;12:3.
55. Watson L, Beresford M W, Maynes C, et al. The indications, efcacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015;24:10-7.
56. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efcacy of ritux-imab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol 2015;42:541-6.
57. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus ery-thematosus. Arthritis Rheum 1996;39:363-9.
58. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumu-lative disease activity and medication use predict disease damage. Arthritis Rheum 2002;46:436-44.
59. Sato JO, Corrente JE, Saad-Magalhães C. Chronic active disease pattern predicts early damage in juvenile systemic lupus erythematosus. Lupus 2015;24:1421-8.
60. Mina R, Klein-Gitelman MS, Nelson S, et al. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis 2014;73:401-6.
61. Levy DM, Peschken CA, Tucker LB, et al. Health related quality of life in childhood-onset systemic lupus erythematosus is associated with ethnicity: Results from a multiethnic multicenter Canadian cohort. Arthritis Care Res 2014;66:1767-74.
62. Schanberg LE, Sandborg C, Barnhart HX, et al.; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012;64:285-96.
63. Rubin HR, Pronovost P, Diette GB. The advantages and disadvantages of process-based measures of health care quality. Int J Qual Health Care 2001;13:469-74.
64. Hollander MC, Sage JM, Greenler AJ, et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus ery-thematosus. Arthritis Care Res (Hoboken) 2013;65:1416-23.
65. Mina R, Harris JG, Klein-Gitelman MS, et al. Initial benchmarking of the quality of medical care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2016;68:179-86.
66. Tunniclife DJ, Singh-Grewal D, Chaitow J, et al. Lupus means sacrifces: perspectives of adolescents and young adults with systemic lupus erythe-matosus. Arthritis Care Res (Hoboken) 2016;68:828-37.
67. Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global fares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011;63:1213-23.
68. Felsenstein S, Reif AO, Ramanathan A. Transition of care and health-related outcomes in pediatric-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015;67:1521-8.
69. KDIGOcommunications. KDIGO Clinical Practice Guideline for Glomer-ulonephritis, 2012. http://kdigo.org/home/glomerulonephritis-gn/.
70. Ruggiero B, Vivarelli M, Gianviti A, et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant 2013;28:1487-96.
71. Levy DM, Peschken CA, Tucker LB, et al. The 1000 Canadian faces of lupus: Influence of ethnicity on disease in the pediatric cohort. Arthritis Care Res 2012;65:152-60.
72. Lewandowski LB, Schanberg LE, Tielman N, et al. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lupus 2016; e-pub ahead of print 3 August 2016.
73. Uziel Y, Gorodnitski N, Mukamel M, et al.; Pediatric Rheumatology Study Group Of Israel @ SLERI. Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus. Lupus 2007;16:142-6.
74. Fish AJ, Blau EB, Westberg NG, Burke BA, Vernier RL, Michael AF. Systemic lupus erythematosus within the frst two decades of life. Am J Med 1977;62:99-117.
75. McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992;89:240-6.
76. Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in ffy-five patients. Clin Immunol Immunopathol 1983;29:196-210.
77. Vyas S, Hidalgo G, Baqi N, Von Gizyki H, Singh A. Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr Nephrol 2002;17:45-9.
78. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and ther-apy. J Am Soc Nephrol 1996;7:924-9.
79. Bogdanovic R, Nikolic V, Pasic S, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004;19:36-44.
80. Vachvanichsanong P, Dissaneewate P, McNeil E. Twenty-two years' expe-rience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 2011;96:44-9.
81. Batinic D, Miloševic D, Coric M, Topalovic-Grkovic M, Jelušic M, Turudic D. Lupus nephritis in Croatian children: clinicopathologic fnd-ings and outcome. Lupus 2015;24:307-14.
82. Hersh AO, Trupin L, Yazdany J, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythe-matosus. Arthritis Care Res (Hoboken) 2010;62:1152-9.
83. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol 2016;68:1432-41.
84. Wu J Y, Yeh K W, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 2014;43:513-20.
85. Singh S, Abujam B, Gupta A, et al. Childhood lupus nephritis in a developing country-24 years' single-center experience from North India. Lupus 2015;24:641-7.
86. Askenazi D, Myones B, Kamdar A, et al. Outcomes of children with prolif-erative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 2007;22:981-6.
87. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007;22:222-31.
88. Nathanson S, Salomon R, Ranchin B, et al. Prognosis of lupus membranous nephropathy in children. Pediatr Nephrol 2006;21: 1113-6.
89. Hugle B, Silverman ED, Tyrrell PN, Harvey EA, Hébert D, Benseler SM. Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatr Nephrol 2015;30:113-21.
90. Hiraki LT, Lu B, Alexander SR, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum 2011;63:1988-97.
91. Bartosh SM, Fine RN, Sullivan EK. Outcome afer transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation 2001;72:973-8.